Using the new NSG-Pro recipient strain with ER+ PDX models, we uncovered evidence of actionable somatic BRCA1/2 pathway disruption in tamoxifen-resistant, isogenic PDX tumor sublines. The gene discussed is BRCA1; the disease is neoplasm.